LABORATORY RESEARCH Dual PI3K/mTOR Inhibitor, XL765 (SAR245409), Shows Superior Effects to Sole PI3K [XL147 (SAR245408)] or mTOR [Rapamycin] Inhibition in Prostate Cancer Cell Models Scientists compared the in vitro effects of the dual PI3K/mTOR inhibitorn with those observed with the sole PI3K or mTOR inhibition in two non-tumor prostate epithelial cell lines, eight prostate cancer cell lines, and 11 prostate cancer cell derivatives. [Tumor Biol] Abstract Downregulation of HMGA2 Inhibits Cellular Proliferation and Invasion, Improves Cellular Apoptosis in Prostate Cancer Researchers explored the expression of high mobility group A2 (HMGA2) in prostate cancer tissues and its correlation to the clinical pathology of prostate cancer, and discussed the role of HMGA2 in the development of prostate cancer. [Tumor Biol] Abstract Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells Investigators report that 2 muM withaferin A induced cell death selectively in androgen-insensitive PC-3 and DU-145 prostate adenocarcinoma cells, whereas its toxicity was less severe in androgen-sensitive LNCaP prostate adenocarcinoma cells and normal human fibroblasts. [PLoS One] Full Article Comparative Metabolomic and Lipidomic Analysis of Phenotype Stratified Prostate Cells Investigators have identified potentially interesting species of different lipid subclasses including phosphatidylcholines, phosphatidylethanolamines, glycerophosphoinositols and other metabolites that are significantly upregulated in prostate cancer cells derived from distant metastatic sites. [PLoS One] Full Article miR-345 Suppresses Proliferation, Migration and Invasion by Targeting Smad1 in Human Prostate Cancer Researchers found that the expression of miR-345 was significantly downregulated in prostate cancer and clinical prostate cancer tissues. Overexpression of miR-345 in prostate cancer cells suppressed proliferation, migration and invasion. [J Cancer Res Clin Oncol] Abstract miR-503 Suppresses Tumor Cell Proliferation and Metastasis by Directly Targeting RNF31 in Prostate Cancer The effect of RNF31 on prostate cancer (PCa) progression was studied in vitro and in vivo. Silence of RNF31 suppressed PCa cell proliferation and metastasis in vitro and in vivo. [Biochem Biophys Res Commun] Abstract Expression and Potential Role of the Peptide Orexin-A in Prostate Cancer Orexin-A administration to the human androgen-dependent prostate carcinoma cells LNCaP up-regulated OX1 receptor expression resulting in a decrease of cell survival. Nnomolar concentrations of the peptide counteracted the testosterone-induced nuclear translocation of the androgen receptor in the cells: the orexin-A action is prevented by the addition of the OX1 receptor antagonist SB-408124 to the test system. [Biochem Biophys Res Commun] Abstract CLINICAL RESEARCH Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer Investigators assigned men with metastatic, hormone-sensitive prostate cancer to receive either androgen-deprivation therapy (ADT) plus docetaxel or ADT alone. The primary objective was to test the hypothesis that the median overall survival would be 33.3% longer among patients receiving docetaxel added to ADT early during therapy than among patients receiving ADT alone. [N Engl J Med] Abstract | Press Release |